CurrentAetnaPolicy 0521

Prostate Cancer Screening

This policy governs medical necessity, coverage, and investigational determinations for prostate cancer screening (PSA and DRE) and related tests for Aetna members. It affects clinicians ordering screening and diagnostic PSA/DRE and payers adjudicating coverage.

Policy Summary

PayerAetna

PolicyProstate Cancer Screening

Policy CodePolicy 0521

Change TypeNo material change

Effective DateFeb 12, 2002

Next Review DateMay 23, 2024

Key ActionProvide shared decision-making information about benefits and harms to patients requesting screening.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

45min age avg-risk

40min age high-risk

75not NMG ≥

G0102,G0103,84152-54covered codes

multipleexperimental tests

76,693large RCT subjects

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Prior Authorization

inv-29: Age / life expectancy limitation — routine screening >=75 not medically necessary unless life expectancy >=10 years

Age / life expectancy limitation: Routine screening in members 75 years or older is not medically necessary unless life expectancy is greater than or equal to 10 years.

Provider action: Document life expectancy assessment and rationale when ordering screening in patients >=75.

Billing and Code References

Covered CPT/HCPCS Codes if selection criteria are metmixedCovered

84152	Prostate specific antigen (PSA); complexed (direct measurement)
84153	Prostate specific antigen (PSA); total
84154	Prostate specific antigen (PSA); free
G0102	Prostate cancer screening; digital rectal examination
G0103	Prostate cancer screening; prostate specific antigen test (PSA)

Codes associated with experimental or not-covered screening testsmixedNot Covered

0021U	Oncology (prostate), detection of 8 autoantibodies, multiplexed immunoassay and flow cytometry serum, algorithm reported as risk score
81210	BRAF gene analysis, V600 variant(s)
81313	PCA3/KLK3 ratio
81539	Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and hK2), prognostic algorithm
84255	Chemistry, Selenium
83520	Immunoassay for analyte other than infectious agent antibody or antigen; quantitative

ICD-10 Codes referencedICD-10

C61	Malignant neoplasm of prostate
D07.5	Carcinoma in situ of prostate
D29.1	Benign neoplasm of prostate
D40.0	Neoplasm of uncertain behavior of prostate
N40.0	Enlarged prostate
R97.20	Elevated prostate specific antigen [PSA]
Z12.5	Encounter for screening for malignant neoplasm of prostate
Z15.03	Genetic susceptibility to malignant neoplasm of prostate
Z80.42	Family history of malignant neoplasm of prostate
Z85.46	Personal history of malignant neoplasm of prostate

inv-13: PSA-based screening frequency guidance (NCCN)

NCCN recommended baseline ageBegin baseline PSA screening at age 45 (panel supports screening through age 75; testing considered only for men with ≥10-year life expectancy)

PSA <1 ng/mL frequencyRepeat screening every 2–4 years for men aged 45–75 with serum PSA <1 ng/mL

PSA 1–3 ng/mL frequencyRepeat screening every 1–2 years for men aged 45–75 with serum PSA 1–3 ng/mL

inv-14: PSA threshold for biopsy in cited trials

Trial biopsy referral PSA thresholdPSA ≥3 ng/mL used in cited randomized screening trials to refer men for biopsy (STHLM3‑MRI, GOTEBORG‑2 and related population trials)

Context of thresholdThreshold applied to invite biopsy workup including MRI and randomization to standard vs MRI‑directed approaches

Age range where threshold appliedApplied in trials enrolling men approximately 50–74 years (STHLM3‑MRI) or 50–60 years (GOTEBORG‑2)

inv-15: Stockholm3 threshold used as safety mechanism

Stockholm3 safety cutoffStockholm3 score ≥25% was used as a safety mechanism in STHLM3‑MRI to recommend standard biopsy despite negative MRI

Role in trial algorithmApplied to men with negative MRI to trigger standard biopsy to avoid missed clinically significant cancers

Availability noteInvestigators acknowledged Stockholm3 is not widely available and performed sensitivity analyses omitting these participants

inv-16: Example higher PSA safety threshold mentioned

Example higher PSA safety thresholdPSA ≥10 ng/mL cited as an alternative safety mechanism for recommending biopsy when MRI is negative

Alternative safety mechanismsOther options include low free PSA or elevated PSA density (PSA/prostate volume) to prompt biopsy

Use in sensitivity analysesAuthors noted sensitivity analyses excluding Stockholm3‑based biopsies had small effect, acknowledging alternative safety thresholds

Provider Responsibilities, Prior Authorization, and Documentation

Billing Rule

Use specified CPT/HCPCS and PSA assay codes for covered screening

When submitting claims for covered screening services, use the listed CPT/HCPCS and PSA assay codes (e.g., G0102 for DRE; G0103 for PSA; 84152–84154 for PSA assays) when the member meets the policy selection criteria.

G0102 — Prostate cancer screening; digital rectal examination
G0103 — Prostate cancer screening; prostate specific antigen test (PSA)
84152, 84153, 84154 — PSA assay codes (complexed, total, free)

Prior Authorization

Non‑PSA blood tests (investigational) — documentation/prior‑auth guidance

Novel non-PSA blood tests (for example, Apifiny) are considered investigational and are not FDA approved; providers offering such tests should document investigational status and provide clinical justification if submitted for coverage consideration.

Background and Evidence Context

Prostate‑specific antigen (PSA) remains the primary biochemical marker used in prostate cancer screening but has limited specificity and contributes to over‑diagnosis and over‑treatment. Major trials cited show increased detection of prostate cancer with PSA screening without a clear reduction in short‑term mortality and substantial downstream biopsy and treatment consequences; shared decision‑making about benefits and harms is recommended when offering screening.

Key Terms and Risk Categories

inv-34: High-risk for prostate cancer — definition and screening age

Definition of high-riskIncludes African‑American men and men with a family history of prostate cancer; men with multiple first‑degree relatives or early‑onset family cases may be at even higher risk

Recommended screening age — high riskBegin PSA screening at age 40 for men at higher risk; discuss starting at age 45 for some high‑risk groups per guideline nuance

Screening life‑expectancy notePSA testing generally offered only to men with a ≥10‑year life expectancy; panel supports screening through age 75 (testing considered only in very healthy men older than 75)

inv-35: Average-risk for prostate cancer — recommended screening ages

Definition of average‑riskMen without identified high‑risk features (no known family history or African ancestry)

Policy Revision History

2002-02-12policy_effective_date

Policy effective date recorded for this Clinical Policy Bulletin.

2023-07-14last_review

Most recent clinical review of the policy was completed.

2024-05-23next_review_scheduledLatest

Next policy review scheduled.

Policy Summary

PayerAetna

PolicyProstate Cancer Screening

Policy CodePolicy 0521

Change TypeNo material change

Effective DateFeb 12, 2002

Next Review DateMay 23, 2024

Key ActionProvide shared decision-making information about benefits and harms to patients requesting screening.

SourceLink

On This Page

Apifiny measures eight prostate-cancer–specific autoantibodies and is not FDA approved.
NCCN Biomarkers Compendium does not list Apifiny.

Note

Prior authorization not specified for MRI/biopsy pathway

The policy text describes diagnostic pathways (PSA → MRI → biopsy) but does not specify payer prior authorization requirements for these steps in the cited sections.

Note

No prior authorization specified in Additional Information

No prior authorization requirements are specified in the additional information section of the policy.

Step Therapy

Consider novel biomarkers only after standard evaluation

Use novel biomarkers only after standard evaluation (PSA/DRE) and when results would be expected to change management, given limited evidence and concerns about over-diagnosis.

Standard PSA/DRE screening remains the common approach; many novel biomarkers lack consistent validation.
Consider novel tests only if they would alter clinical management after established evaluation.

Note

Sequential PSA → MRI → targeted biopsy pathway used in trials

Clinical trials described a sequential diagnostic pathway: initial PSA screening with referral for MRI if PSA is elevated (e.g., ≥3 ng/mL), followed by targeted biopsy (with or without systematic biopsy depending on trial arm).

STHLM3-MRI and GOTEBORG-2 trials used PSA ≥3 ng/mL as a threshold to refer for MRI.
Trials randomized men to MRI-targeted strategies (targeted-only or targeted+systematic) versus standard biopsy.

Documentation Required

Shared decision‑making required for screening requests

Providers should engage in shared decision-making and provide objective information about potential benefits and harms of prostate cancer screening to patients who request screening.

Discuss benefits, limitations, and uncertainties of early detection and treatment.
Clinician discretion in decision to perform routine PSA/DRE screening is emphasized.

Documentation Required

Required clinical documentation for screening interpretation

Maintain clinical documentation that supports interpretation of screening and biopsy decisions, including PSA values, DRE findings, biopsy outcomes (benign, indolent, clinically significant), and ancillary test results (e.g., PSA velocity, PSA fractions) when relevant.

Record PSA and DRE results and any prior elevated PSAs or symptoms prompting testing.
Document biopsy classification and any ancillary biomarker results used to guide decisions.

Documentation Required

Safety triggers for negative MRI (Stockholm3 ≥25%)

As a safety mechanism used in the STHLM3‑MRI trial, men with negative MRI but Stockholm3 scores ≥25% were recommended to undergo standard biopsy; alternative safety triggers in practice could include high PSA (e.g., ≥10 ng/mL), low free PSA, or elevated PSA density.

Stockholm3 score ≥25% prompted standard biopsy despite negative MRI in the trial.
Other safety criteria mentioned include PSA ≥10 ng/mL, free PSA, and PSA density.

Note

Refer to Aetna resources and notices for plan‑specific details

See Aetna resources (Glossary, Program Provisions, Plan Disclosures) and Clinical Policy Bulletin notes for additional information; the policy contains legal and administrative disclaimers about coverage and plan-specific provisions.

Additional links and notices are provided in the Additional Information section.
Clinical Policy Bulletins are not offers of coverage and may be updated.

Denial Risk

Screening may increase detection and over‑diagnosis without short‑term mortality benefit

Randomized trial evidence cited shows screening increases cancer detection without reducing short‑term mortality and can lead to substantial over‑diagnosis and over‑treatment; providers should consider these outcomes when recommending screening.

Large RCT (n=76,693) found higher incidence with screening but no reduction in deaths at 7 years.
Many men with low‑risk tumors subsequently receive aggressive treatment.

Note

MRI plus targeted biopsy reduces unnecessary biopsies and over‑diagnosis

Trials indicate MRI with targeted biopsy strategies reduce unnecessary biopsies and the detection of clinically insignificant cancers compared with standard biopsy, which may inform biopsy referral practices.

STHLM3-MRI reported fewer biopsies and fewer clinically insignificant cancers with MRI-directed approaches.
GOTEBORG-2 found targeted-only biopsy reduced clinically insignificant diagnoses by ~50%.

Note

No explicit authorization or denial triggers provided

The policy sections provided do not list specific authorization or denial triggers; administrative and legal disclaimers note plan-level differences and that the Clinical Policy Bulletin is not a coverage contract.

Recommended screening age — average risk

Begin baseline PSA screening at age 45 for average‑risk men (NCCN recommendation)

Screening frequency guidanceFollow NCCN frequency guidance based on PSA level (e.g., every 2–4 years if PSA <1 ng/mL; 1–2 years if PSA 1–3 ng/mL)

inv-36: PSA velocity (PSAV) definition and role

PSAV definitionPSA velocity (PSAV) is the rate of change of PSA over time, calculated across serial PSA measurements

Role in studiesPSAV cut‑offs reduced the number of biopsies in ERSPC subset analyses but led to important numbers of missed clinically significant cancers

LimitationsPSAV was not an independent predictor of prostate cancer or clinically significant cancer in multivariate analysis and therefore should not be used as the sole biopsy indicator

inv-37: Apifiny — definition and regulatory status

What Apifiny measuresApifiny is a non‑PSA blood test that measures eight prostate‑cancer‑specific autoantibodies in serum (e.g., ARF6, NKX3‑1, BMI1 UTR targets, others)

MethodologyUses immunoassay, flow cytometry, and an algorithmic score reported as risk

Regulatory/status noteApifiny is not FDA approved and is not listed in the NCCN Biomarkers Compendium per cited sources

inv-38: GWAS SNP profile — brief definition

DefinitionA GWAS SNP profile is an aggregate single‑nucleotide polymorphism risk profile derived from genome‑wide association studies (GWAS)

Scope of discoveriesApproximately 170 SNPs associated with prostate cancer risk have been identified in large GWAS efforts

Risk explainedThese SNPs can explain over ~30% of prostate cancer risk in aggregate according to cited analyses

inv-39: Clinically significant prostate cancer — trial definition (e.g., Gleason ≥7)

Trial definition (common)Clinically significant prostate cancer in the cited trials was defined commonly as Gleason score ≥7 (e.g., used as primary outcome in STHLM3‑MRI)

STHLM3‑MRI specificsPrimary outcome was diagnosis of clinically significant cancer defined as Gleason ≥7 in population‑based trial comparing MRI‑directed vs standard biopsy

Implication for screening algorithmsMRI‑targeted approaches were non‑inferior for detecting Gleason ≥7 cancers while reducing detection of clinically insignificant cancers

inv-40: Clinically insignificant prostate cancer — trial definition (e.g., Gleason 3+3)

Trial definition (common)Clinically insignificant prostate cancer was defined in GOTEBORG‑2 and related trials as Gleason score 3+3

GOTEBORG‑2 outcomeThe primary outcome in GOTEBORG‑2 was clinically insignificant PCa (Gleason 3+3), with MRI‑targeted‑only biopsy reducing such diagnoses by ~50%

Clinical implicationReducing detection of Gleason 3+3 cancers addresses over‑diagnosis and potential overtreatment in population screening settings